Cartalax
A synthetic tripeptide bioregulator (Ala-Glu-Asp) from the Khavinson system, studied for cartilage protection, joint health, and musculoskeletal aging.
What is Cartalax?
Cartalax is a synthetic tripeptide consisting of alanine, glutamic acid, and aspartic acid (Ala-Glu-Asp), developed as part of Vladimir Khavinson's bioregulator peptide system at the St. Petersburg Institute of Bioregulation and Gerontology. Its amino acid sequence corresponds to a motif found in the alpha-1 chain of type XI collagen, a structural protein important for cartilage integrity. It is classified as a Cytogen — a lab-synthesized short peptide designed to mirror the regulatory effects of peptides naturally found in cartilage tissue. Its natural-extract counterpart is Sigumir, a complex of peptides derived from animal cartilage and bone tissue.
What Cartalax Is Investigated For
Cartalax is a synthetic tripeptide from Vladimir Khavinson's bioregulator program investigated for cartilage protection, joint health, osteoarthritis, osteochondrosis, and anti-senescence effects in connective tissue cells. The strongest available evidence consists of in vitro chondrocyte studies from the Khavinson group reporting 18-38% increases in cartilage area index, MMP-9 inhibition, SIRT6 upregulation, and reduced senescence markers — supported by a structural rationale that the Ala-Glu-Asp sequence matches a motif in type XI collagen. The central honest caveat is that the entire evidence base comes from a single research orbit: there are no PubMed-indexed human RCTs, no independent Western replication of the in vitro findings, and the Khavinson program's central claim of direct DNA interaction by a tripeptide remains contested in the broader scientific community. Russian clinical reports of benefit in spinal osteochondrosis and osteoarthrosis are not indexed in Western databases and do not meet modern trial-methodology standards. Cartalax is not FDA-approved, not on the 503A compounding list, and not part of mainstream Western orthopedic practice.
History & Discovery
Cartalax was developed by Vladimir Khavinson's bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology, as part of an effort to map short synthesized peptides to specific tissue-maintenance functions of larger natural-extract preparations. The natural-extract counterpart is Sigumir, a peptide complex from animal cartilage and bone tissue that the Khavinson group had studied for several decades. The synthesized tripeptide Ala-Glu-Asp (AED) was identified on the basis that its sequence matches a motif found in the alpha-1 chain of type XI collagen — a structural protein critical to cartilage integrity — and the hypothesis was that delivering this minimal sequence exogenously would help reactivate cartilage-maintenance gene programs that decline with age. The published research base for Cartalax specifically is thin: it consists primarily of in vitro chondrocyte studies from the Khavinson group reporting effects on proliferation markers, sirtuin expression, MMP-9 inhibition, and senescence indicators. Independent Western replication of these in vitro findings has not occurred at scale, and there are no PubMed-indexed human RCTs for Cartalax. The clinical evidence cited in Russian Khavinson-program publications, including reports of effectiveness in spinal osteochondrosis, osteoarthrosis, and osteoporosis, is not independently indexed and has not been reproduced under Western trial-methodology standards.
How It Works
Cartalax is a tiny three-amino-acid peptide proposed to enter cartilage cells and interact with their DNA, reactivating genes involved in maintaining healthy cartilage. As we age, cartilage cells produce less collagen and protective matrix — Cartalax is thought to help reverse that decline by boosting the cell's own repair programs.
Cartalax (Ala-Glu-Asp) is proposed to penetrate cell membranes due to its small molecular size (~333 Da) and interact directly with DNA regulatory regions in chondrocytes and fibroblasts. In vitro studies from the Khavinson group report that Cartalax upregulates Ki-67 (proliferation marker), increases SIRT1 and SIRT6 expression (longevity-associated sirtuins), and reduces p53 and caspase-3 activity (pro-apoptotic signals). It inhibits MMP-9 synthesis, an enzyme responsible for extracellular matrix degradation that increases with aging. Cartalax has been reported to increase cartilage area index by 18-38% in chondrocyte cultures from both young and old specimens. The peptide may also modulate Wnt/beta-catenin signaling and stimulate synthesis of type II collagen and aggrecan — both essential for cartilage resilience and elasticity.
Evidence Snapshot
Human Clinical Evidence
Very limited for Cartalax specifically. A clinical study in the Khavinson program established effectiveness of adjunctive Cartalax treatment in patients with spinal osteochondrosis, osteoarthrosis, and osteoporosis, but this study is not indexed in PubMed. The natural-extract counterpart Sigumir has additional clinical data from Russian studies.
Animal / Preclinical
Moderate within the Khavinson framework. In vitro chondrocyte studies show increased proliferation (18-38% cartilage area index increase), MMP-9 inhibition, SIRT6 upregulation, and reduced senescence markers (p16, p21). The broader Khavinson short-peptide research program demonstrates nuclear penetration and DNA binding by small peptides (PMID: 27909961).
Mechanistic Rationale
Moderate. The AED sequence corresponds to a motif in type XI collagen, providing a structural rationale. The proposed mechanism of cartilage-specific gene reactivation through direct DNA interaction is supported by in vitro data from the originating research group, but has not been independently replicated.
Research Gaps & Open Questions
What the current literature has not yet settled about Cartalax:
- 01Independent replication outside the Khavinson research program — in vitro chondrocyte effects have not been reproduced by Western laboratories under modern standards.
- 02Blinded randomized controlled trials in humans for osteoarthritis, osteochondrosis, or any joint-health endpoint.
- 03Pharmacokinetics in humans — absorption (particularly oral and sublingual bioavailability of the intact tripeptide), distribution to cartilage tissue, and clearance have not been characterized.
- 04Mechanism specificity — direct DNA interaction by a tripeptide and the resulting cartilage-specific gene reactivation claim has not been independently validated.
- 05Long-term safety, particularly any effect on cartilage remodeling that could become problematic with chronic use or in subclinical malignancy.
- 06Theoretical cancer-promotion concern — agents that stimulate cellular proliferation in connective tissue raise class concerns for tumor risk that the available data does not adequately address.
Forms & Administration
Cartalax is available in capsule, sublingual, and injectable formats. Capsule protocols typically involve 1-2 capsules daily for 10-30 days. Injectable protocols use subcutaneous administration. All peptides should only be used under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Russian Khavinson-affiliated capsule products typically deliver low milligram-range doses formulated for sublingual or oral administration. Research-chemical injectable Cartalax is sold for subcutaneous use at 100–200 mcg per dose. There is no published independent dose-finding study.
Frequency
Daily administration during the course — typically 1–2 capsules per day for oral forms, or once-daily SC injection for injectable forms.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
10–30 day courses repeated every 3–6 months — a characteristic feature of Khavinson protocols. Continuous long-term daily use is not part of the published Khavinson regimen.
Protocol Notes
Russian Khavinson-affiliated capsule and sublingual products are marketed as dietary peptide complexes (Peptides.ru and similar brands) rather than as registered pharmaceuticals. Research-chemical injectable Cartalax is supplied as lyophilized powder requiring reconstitution in bacteriostatic water. Western clinicians do not generally prescribe Cartalax; protocols outside Russia rely on convention rather than anchored clinical guidance. Oral and sublingual bioavailability of intact short peptides is uncertain — the Khavinson group's claims of intact-peptide absorption have not been confirmed by independent pharmacokinetic study.
Claims for cartilage protection, joint health, and connective-tissue restoration exceed what the evidence base — dominated by in vitro work from a single program — can independently support. Not FDA-approved. Russian protocols come from a single-lab tradition not validated by Western-standard trials. Research-chemical supply outside Russian channels is not authorized for human use.
Timeline of Effects
Onset
Not characterized in controlled clinical studies. Russian clinical reports describe symptomatic improvements (joint pain, mobility) over the duration of a 10–30 day course. There is no characterized acute onset profile.
Peak Effect
Khavinson protocols measure outcomes at the end of a 10–30 day course and at follow-up. Cartilage remodeling, if it occurs as the in vitro mechanism suggests, would be expected to develop over weeks to months rather than acutely.
After Discontinuation
No documented withdrawal or rebound. Symptomatic effects, when reported, typically fade over weeks of cessation, which is the rationale for the periodic-repeat-course schedule. Long-term cumulative effects from repeated courses across years have not been independently studied.
Common Questions
Who Cartalax Is NOT For
- •Pregnancy — no adequate reproductive toxicology data; not recommended.
- •Breastfeeding — no data on transfer or infant effects.
- •Active or recent-history malignancy — agents proposed to reactivate cellular proliferation and gene expression raise theoretical tumor-promotion concerns that have not been adequately studied; oncology clinician input warranted.
- •Pediatric use — no safety or developmental data; cartilage-active agents in growing children are particularly concerning without developmental safety data.
- •Known hypersensitivity to peptide preparations or to excipients used in capsule or injectable formulations.
- •Compromised injection-site skin integrity or known infection — research-chemical supply sterility cannot be assumed and raises injection-site infection risk absent from clinic-supplied medication.
Drug & Supplement Interactions
Documented clinical drug interactions for Cartalax are essentially absent; no formal interaction studies meeting Western standards have been published. Theoretical class concerns include concurrent use with chemotherapy or anti-proliferative agents, where Cartalax's proposed proliferation-stimulating effect on chondrocytes could be mechanistically opposed. Combination with other joint-active medications (NSAIDs, intra-articular corticosteroids, hyaluronate injections, glucosamine/chondroitin supplements) has not been formally studied for interaction. Patients on any regular medication should disclose Cartalax use to their prescribing clinician.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved
- • Clinical data is limited and primarily from Russian research
- • Quality and purity vary significantly by source
- • Should be used under clinician guidance
What We Don't Know
Western clinical trial data is absent. Most evidence comes from the Khavinson research program. Long-term safety of chronic use has not been evaluated in controlled Western studies. The claimed mechanism of direct DNA interaction by a tripeptide remains debated in the broader scientific community.
Legal Status
United States
Not FDA-approved for any indication. Not recognized as a dietary supplement ingredient. Not on the FDA's list of peptides eligible for 503A compounding. Injectable forms sold primarily through research-chemical suppliers not authorized for human use. Russian capsule products are sometimes imported informally; legitimate clinical access pathways are essentially absent.
International
Russian Khavinson-affiliated capsule and sublingual products are marketed as dietary peptide complexes under brands like Peptides.ru. Limited availability through informal CIS distribution. Not approved by EMA, MHRA, Health Canada, or TGA.
Sports & Competition
Not specifically named on the WADA Prohibited List. As an unapproved substance for therapeutic use in most WADA-code jurisdictions, the WADA S0 catch-all category likely applies to injectable forms. Athletes subject to WADA code should treat injectable Cartalax as prohibited.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Cartalax has been proven to regenerate cartilage in osteoarthritis patients.
Reality
It has not. The published evidence consists primarily of in vitro chondrocyte studies from the Khavinson group plus non-PubMed-indexed Russian clinical reports. There are no blinded randomized controlled trials in osteoarthritis or any joint-health condition meeting Western trial-methodology standards.
Myth
Because Cartalax matches a sequence in type XI collagen, it must work to support cartilage.
Reality
Sequence homology to a structural protein motif is a hypothesis-generating observation, not a demonstration of clinical effect. Many short peptide sequences match motifs in larger proteins without retaining or recapitulating the larger protein's function. The mechanistic argument is plausible but does not substitute for clinical evidence of efficacy.
Myth
Russian dietary-complex registration means Cartalax is approved as a medicine.
Reality
Russian Khavinson-affiliated capsule products are marketed as dietary peptide complexes, not as registered pharmaceuticals. This is a different regulatory category with lower evidence requirements than prescription-medicine approval and is not equivalent to approval by EMA, FDA, or other Western regulatory bodies.
Myth
Vladimir Khavinson won the Nobel Prize for peptide bioregulator research, so the Cartalax claims are well-validated.
Reality
He did not win the Nobel Prize, and persistent online attributions are inaccurate. The Khavinson program has published extensively, but the body of work has not been recognized at that level and core claims have not been independently replicated in Western laboratories.
Myth
Because Cartalax is just three amino acids, it is essentially harmless.
Reality
Small molecular size does not imply safety. If the claimed mechanism — proliferation stimulation in chondrocytes through direct DNA interaction — is real, that is precisely the kind of activity that requires careful safety evaluation, particularly in patients with subclinical malignancy. Safety has to be established by data, not inferred from molecular weight.
Published Research
6 studiesPeptides for Targeting Chondrogenic Induction and Cartilage Regeneration in Osteoarthritis
Peptide Regulation of Chondrogenic Stem Cell Differentiation
The most Cartalax-specific paper in the literature — reports chondrogenic differentiation effects of the AED tripeptide on mesenchymal stem cells, the anchor paper for Cartalax's cartilage-targeting claims.
Peptide Regulation of Gene Expression: A Systematic Review.
Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides.
Peptide Regulation of Cell Differentiation.
Short Peptides Regulate Gene Expression.
Quick Facts
- Class
- Bioregulator Peptide
- Tier
- D
- Evidence
- Preliminary
- Safety
- Limited Data
- Updated
- Apr 2026
- Citations
- 6PubMed
Also known as
Tags
Peptide Families
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.